Elite in Nelson Syndrome

Richard A. Feelders

Erasmus MC
Rotterdam, ZH, NL 
Elite in Nelson Syndrome
Erasmus MC
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Richard Feelders practices in Rotterdam, Netherlands. Mr. Feelders is rated as an Elite expert by MediFind in the treatment of Nelson Syndrome. His top areas of expertise are Cushing's syndrome, Cushing's disease, Adrenal Cancer, Nelson Syndrome, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 220 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Nelson Syndrome.

Gender
Male

Locations

Erasmus MC
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
A European, Multi-Centre, Multi-Country, Post-Authorisation, Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
A European, Multi-Centre, Multi-Country, Post-Authorisation, Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
Enrollment Status: Terminated
Publish Date: October 15, 2024
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

220 Total Publications

Update on Medical Treatment of Cushing's Syndrome.
Update on Medical Treatment of Cushing's Syndrome.
Journal: Drugs
Published: July 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Feelders's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile